propranolol   Click here for help

GtoPdb Ligand ID: 564

Synonyms: Bedranol® | Hemangiol® | Inderal® | propranolol hydrochloride
Approved drug
propranolol is an approved drug (FDA (1967), EMA (2014))
Compound class: Synthetic organic
Comment: The approved drug propranolol is a racemic mixtue of (+)-propranolol and propranolol. We show the non-stereo molecule to represent the mixture.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 41.49
Molecular weight 259.16
XLogP 3.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(COc1cccc2c1cccc2)CNC(C)C
Isomeric SMILES OC(COc1cccc2c1cccc2)CNC(C)C
InChI InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChI Key AQHHHDLHHXJYJD-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
2. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
3. Baker JG, Adams LA, Salchow K, Mistry SN, Middleton RJ, Hill SJ, Kellam B. (2011)
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
J Med Chem, 54 (19): 6874-87. [PMID:21870877]
4. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.
ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874]
5. Baker JG, Hall IP, Hill SJ. (2003)
Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Mol Pharmacol, 64 (3): 679-88. [PMID:12920204]
6. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025)
Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor.
Mol Pharmacol, 107 (11): 100081. [PMID:41289653]
7. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]
8. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.
Br J Pharmacol, 112 (3): 911-9. [PMID:7921620]
9. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. (1999)
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Eur J Pharmacol, 367 (2-3): 431-5. [PMID:10079020]
10. Pietri-Rouxel F, Strosberg AD. (1995)
Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors.
Fundam Clin Pharmacol, 9 (3): 211-8. [PMID:7557816]
11. Popp BD, Hutchinson DS, Evans BA, Summers RJ. (2004)
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
Eur J Pharmacol, 484 (2-3): 323-31. [PMID:14744619]
12. Proudman RGW, Baker JG. (2025)
A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD.
Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869]
13. Smith C, Teitler M. (1999)
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors.
Cardiovasc Drugs Ther, 13 (2): 123-6. [PMID:10372227]